Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary)
- Indications Neuroblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms MATCH
- 03 Oct 2023 Planned End Date changed from 31 Dec 2024 to 1 Oct 2024.
- 06 Jun 2023 Results (n=20), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 08 Apr 2023 Status changed from suspended to active, no longer recruiting.